DEERFIELD, Ill.--(BUSINESS WIRE)--Results from an investigator-initiated study, which evaluated whether prophylactic use of FEIBA [Anti-inhibitor Coagulant Complex] can achieve a decrease in the frequency of joint and other bleeding events in patients with severe hemophilia A and inhibitors compared to on-demand therapy, were published today in The New England Journal of Medicine. Patients with severe hemophilia A and inhibitors are at increased risk for serious bleeding complications. Effective strategies to prevent bleeding in inhibitor patients have not yet been established. Prophylaxis, where approved, is used to prevent a bleed and on-demand treatment is used only at the time of a bleeding episode.
